8-K: Myriad Genetics Reports Mixed Q1 2025 Results, Updates Financial Guidance

Myriad Genetics' Q1 2025 revenue declined 3% year-over-year, but the company updated its full-year financial guidance to reflect these results and the current business outlook.

Summary

• Myriad Genetics announced its financial results for the first quarter of 2025.
• Revenue for Q1 2025 was $196 million, a 3% decrease year-over-year; excluding headwinds, revenue increased 5%.
• Prenatal revenue grew 11% year-over-year, while Pharmacogenomics revenue declined by 20% due to reduced coverage of GeneSight by UnitedHealthcare.
• MyRisk testing volume in the affected population grew 11% year-over-year.
• The gross margin for Q1 2025 was 69%, a 40 basis point increase year-over-year.
• GAAP net loss was $0.1 million, or $0.00 EPS, driven by a $29 million tax benefit, while adjusted EPS was $(0.03).
• The company updated its 2025 financial guidance, projecting revenue in the range of $807 $823 million and adjusted EPS in the range of $(0.02) $0.02.
• Test volumes in Q1 2025 increased 1% year-over-year to 385,000.
• Cash and cash equivalents totaled $92 million at the end of Q1 2025, with an additional $42 million available under its asset-based credit facility.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While there are some positive aspects like growth in prenatal testing and cost management efforts, the overall revenue decline, lowered guidance, and challenges in the pharmacogenomics business temper the outlook.

Positives

• Prenatal testing revenue grew 11% year-over-year.
• Gross margin increased by 40 basis points to 69% due to greater laboratory efficiencies.
• MyRisk testing volume in the affected population grew 11% year-over-year.
• The company is taking steps to reduce overall expenditures while prioritizing investment in new product development and programs intended to drive revenue growth.
• Myriad intends to commercially launch its first AI-driven prostate cancer test, in partnership with PATHOMIQ, by the end of 2025.

Negatives

• Overall revenue declined by 3% year-over-year.
• Pharmacogenomics revenue decreased by 20% year-over-year due to UnitedHealthcare's reduced coverage of GeneSight.
• The company lowered its 2025 financial guidance.
• Operating loss in the first quarter of 2025 was $29.0 million, an increase of $1.1 million year-over-year.
• First quarter 2025 cash flow used in operations was $16.3 million.

Risks

• Sales and profit margins of the company's existing tests may decline.
• The company may not be able to operate its business on a profitable basis.
• Changes in governmental or private insurers coverage and reimbursement levels for the company's tests could negatively impact revenue.
• Increased competition and the development of new competing tests could affect market share.
• The company may be unable to develop or achieve commercial success for additional tests in a timely manner, or at all.
• The company may not be able to secure additional financing to fund its business, if needed, in a timely manner or on favorable terms, if it all.

Future Outlook

Myriad Genetics updated its full-year 2025 financial guidance, projecting revenue in the range of $807 $823 million and adjusted EPS in the range of $(0.02) $0.02.

Management Comments

• 'We had a challenging first quarter of 2025 with strength in our prenatal and oncology MyRisk tests offset by softness in GeneSight and unaffected hereditary cancer tests,' said Sam Raha, President and CEO, of Myriad Genetics.
• Sam Raha stated that the company is lowering its 2025 financial guidance and taking immediate steps to reduce overall expenditures while prioritizing investment in new product development and programs intended to drive revenue growth.
• The new leadership team is focused on unlocking Myriad Genetics' potential by implementing a compelling strategy, strengthening organizational capabilities, and improving execution.

Industry Context

Myriad Genetics operates in the molecular diagnostics and precision medicine industry, facing competition from companies offering similar genetic testing services. The reduction in GeneSight coverage by UnitedHealthcare highlights the challenges in maintaining reimbursement levels and market access in the evolving healthcare landscape. The company's focus on new product development, such as the AI-driven prostate cancer test, reflects the industry's trend towards leveraging advanced technologies to improve diagnostic accuracy and personalized treatment decisions.

Comparison to Industry Standards

• It's difficult to directly compare Myriad's results without specific competitor data for Q1 2025.
• However, companies like Exact Sciences (EXAS) and Guardant Health (GH) are key players in cancer diagnostics, and their performance in similar periods would provide a benchmark.
• In the prenatal testing space, companies like Natera (NTRA) and Illumina (ILMN) are major competitors, and comparing growth rates in prenatal revenue would be relevant.
• The 20% decline in Pharmacogenomics revenue due to UNH coverage changes is a significant headwind, and it would be useful to see how other companies in the pharmacogenomics space are navigating similar reimbursement challenges.
• Myriad's gross margin of 69% is a key indicator of efficiency, and comparing this to the gross margins of its competitors would provide insights into its operational performance.

Stakeholder Impact

• Shareholders will be impacted by the lowered financial guidance and the company's efforts to reduce expenditures.
• Employees may be affected by the cost reduction initiatives, potentially leading to restructuring or reduced investment in certain areas.
• Customers will be impacted by the company's focus on new product development and the evolution of its testing portfolio.
• Payors, such as UnitedHealthcare, are influencing the company's revenue through coverage decisions.
• Suppliers may be affected by the company's cost management efforts.

Next Steps

• The company intends to commercially launch its first AI-driven prostate cancer test, in partnership with PATHOMIQ, by the end of 2025.
• Myriad Genetics will hold a conference call on May 6, 2025, to discuss the financial results and business developments for the first quarter of 2025.

Key Dates

Keywords

Myriad Genetics, financial results, earnings, revenue, guidance, molecular diagnostics, precision medicine, prenatal testing, pharmacogenomics, oncology, GeneSight, MyRisk, EPS